Meningococcus
Meningococcus is a bacterium that can cause meningitis, an infection of the membranes around the brain and spinal cord, and dangerous bloodstream infection. It lives in the human nose and throat and spreads between people through respiratory particles or throat secretions. Carrying the bacterium usually causes no illness, but sometimes it enters the body and causes rapidly progressing disease. Symptoms can include fever, severe headache, neck stiffness, confusion and vomiting. Bloodstream infection can cause fast breathing, cold hands and feet, low blood pressure and a rash that does not fade under pressure. Suspected disease needs urgent medical assessment and hospital treatment. Antibiotics are used against meningococcal disease, and vaccines protect against particular groups of the bacterium. Disease occurs worldwide, with the greatest burden in the African meningitis belt. Crowded settings and large gatherings can support outbreaks. WHO reported pilgrimage-associated cases in 2025 and highlighted vaccination gaps and the risk of international spread. The retrieved sources do not establish a general incubation period or reproduction number.
Key facts
| Transmission | Person-to-person spread through respiratory particles or throat secretions; the bacterium can be carried without symptoms in the nose and throat. |
|---|---|
| Incubation | unknown |
| Case fatality | A 1991 Norwegian vaccine-trial abstract reported case fatality of about 10% in that setting, without distinguishing treatment status. A general meningococcus-specific estimate with and without treatment is unknown from the retrieved literature and WHO text. |
| Reproduction number | unknown |
| Vaccine | Licensed meningococcal vaccines exist. MenACWY protects against groups A, C, W and Y; group A conjugate vaccination has reduced group A disease in the African meningitis belt. |
| Treatment | Urgent hospital treatment; antibiotics and preventive antibiotics for selected contacts are established approaches. Specific regimens were not available in the retrieved text. |
| Reservoir | Humans; the bacterium naturally lives on the lining of the nose and throat. |
| Endemic regions | Worldwide, with the highest burden in the African meningitis belt, from Senegal to Ethiopia. |
Transmission
Meningococcus spreads between people through respiratory particles or throat secretions. Its natural reservoir is humans: it can live on the lining of the nose and throat without causing illness. Carrying the bacterium is not the same as having meningitis. Occasionally, it invades the body and causes serious infection. Crowding and close proximity help transmission, including in military camps, displaced-person settings and large religious or sporting gatherings. WHO identifies low vaccination coverage and disrupted access to health care as conditions that make outbreaks more likely. The retrieved sources do not establish an incubation period or a general reproduction number.
- Meningitis WHO
- Update on meningococcal disease with emphasis on pathogenesis and clinical management. Europe PMC · 1 Jan 2000
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
Symptoms and severity
Meningococcal disease can cause meningitis or a dangerous bloodstream infection, sometimes together. Meningitis symptoms include fever, headache, neck stiffness, confusion, sensitivity to light, nausea and vomiting. Babies may feed poorly, become unusually inactive or difficult to wake, or develop a bulging soft spot on the head. Bloodstream infection can quickly cause sepsis, a life-threatening illness, with cold hands and feet, fast breathing and low blood pressure. A rash that does not fade under pressure may appear. Survivors can have hearing loss, neurological difficulties or limb damage. A 1991 Norwegian study reported about 10% case fatality in its setting; that is not a universal or current estimate.
- Meningitis WHO
- Meningococcal disease Wikipedia
- Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Europe PMC · 1 Nov 1991
Treatment and vaccines
Suspected meningococcal disease needs urgent medical assessment because it can progress rapidly. Antibiotic treatment and preventive antibiotics for selected contacts are established approaches, but the retrieved texts do not provide enough detail to give a drug regimen. People living with someone who has bacterial meningitis should discuss preventive antibiotics with a clinician. Vaccines offer protection against particular meningococcal groups. MenACWY covers groups A, C, W and Y. WHO reports that group A conjugate vaccination has reduced group A meningitis, although other groups still cause epidemics. In its 2025 pilgrimage notice, WHO advised meningococcal vaccination at least 10 days before travel to Hajj or Umrah.
- Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Europe PMC · 1 Jun 2007
- Meningitis WHO
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
- Meningococcal disease – Nigeria WHO · 24 Mar 2017
Where it occurs
Meningococcal disease occurs worldwide as isolated cases, clusters and epidemics. The greatest burden is in the African meningitis belt, stretching from Senegal to Ethiopia, where recurrent meningococcal meningitis epidemics remain a concern. WHO's fact sheet reports 21,526 suspected meningitis cases and 971 deaths from 24 surveillance countries in 2025. These are suspected meningitis totals, not confirmed meningococcal cases alone. Risk also depends on local conditions: crowded accommodation, displacement, migration and large gatherings can support outbreaks. Pilgrimage-associated cases reported in Saudi Arabia and among returning travelers show how disease can cross borders. A country's absence from this site's archive does not establish that disease is absent there.
- Meningitis WHO
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
- Global epidemiology of meningococcal disease. Europe PMC · 27 May 2009
Recent history
As of 2026-11-15, this site's archive lookup returned zero events under the meningococcus key. The supplied site inventory nevertheless lists a closed record titled “Meningococcal disease outbreak in Kent, United Kingdom.” This discrepancy means the zero count should not be read as an absence of outbreaks. WHO's retrieved notices include outbreaks in Niger, Nigeria, Togo and Liberia. Its 2025-04-11 Saudi Arabia notice described 17 pilgrimage-associated cases reported in 2025 up to that notice, including cases among returning travelers. It also described 12 pilgrimage-associated cases reported in 2024. These figures are historical snapshots, not totals through 2026-11-15; no later WHO notice was retrieved.
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
- Meningococcal septicaemia associated with attending a funeral – Liberia WHO · 6 Jul 2017
- Meningococcal disease – Nigeria WHO · 24 Mar 2017
- Meningococcal disease – Togo WHO · 23 Feb 2017
What to watch
Important warning signals include rising case numbers, clusters in new regions, spread among travelers and sustained transmission in crowded communities. Human-to-human transmission is already established; the concern is an increase in its extent, not its first appearance. Changes in the meningococcal groups causing outbreaks matter because vaccines cover particular groups. Antibiotic resistance also needs monitoring: WHO reported ciprofloxacin-resistant strains in three pilgrimage-associated cases in 2024. Vaccination gaps are another signal. Saudi authorities estimated only 54% compliance with international Umrah pilgrims' vaccination requirements on 2025-03-10. Vaccine shortages, delayed campaigns or disrupted health care would warrant attention, although the retrieved sources do not document a current vaccine shortage.
- Invasive meningococcal disease - Kingdom of Saudi Arabia WHO · 11 Apr 2025
- Meningococcal disease – Togo WHO · 23 Feb 2017
- Meningitis WHO